Cullinan Therapeutics Has Submitted An Investigational New Drug Application To FDA To Evaluate Its CD19xCD3 Bispecific T Cell Engager, CLN-978, For Systemic Lupus Erythematosus
Portfolio Pulse from Benzinga Newsdesk
Cullinan Therapeutics has submitted an Investigational New Drug (IND) application to the FDA for its CD19xCD3 bispecific T cell engager, CLN-978, aimed at treating systemic lupus erythematosus.
September 16, 2024 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cullinan Therapeutics has taken a significant step by submitting an IND application to the FDA for CLN-978, targeting systemic lupus erythematosus. This could lead to new treatment options and potential market expansion.
The submission of an IND application is a critical step in drug development, indicating progress in Cullinan's pipeline. If approved, it could lead to clinical trials and eventually a new product in the market, positively impacting CGEM's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100